This paper describes cases of spinal cord inflammation associated with HTLV-1 in people, not cats. The review includes 45 cases, but follow-up was limited and information on some tests used to assess other diagnoses was missing. Whether the short-term changes reflect changes in the long-term course of the disease remains unknown. The paper provides no direct evidence about FeLV or clinical outcomes in cats.
Scientific detail
Published in 2026 in Neurology(R) neuroimmunology & neuroinflammation (DOI: 10.1212/nxi.0000000000200570), this paper combines a case report with a review of published human cases of rapidly progressive or relapsing HTLV-1-associated myelitis. The review pools the index patient's data with systematically collected published cases that included spinal imaging. The RESULTS section reports 45 cases, including the index case, across 27 publications; Table 2 presents outcome-related data for a subset of 33 cases. This is a descriptive study without a described controlled comparison group, and the spinal imaging requirement constrains case selection.
Among the reviewed human cases, the RESULTS section reports radiographic myelitis in 98%, longitudinally extensive myelitis in 91%, and focal myelitis in 7%. Both the RESULTS section and Table 2 report 91% for longitudinally extensive lesions, whereas the abstract reports 93%. These proportions describe selected published cases; they are not population prevalence estimates or validated measures of diagnostic performance.
Testing for AQP4 and MOG IgG was not reported in cases published before 2009, and reporting was incomplete in cases published subsequently. Unreported testing is not a negative result, and this limitation does not itself establish that any case was misclassified. The authors identify limited longitudinal follow-up and incomplete or historically unavailable antibody testing. Quantitative HTLV-1 PCR was commercially unavailable in some countries, including the United States. In the index case, access barriers prevented whole-body PET, subsequent in-person reassessment, and repeat diagnostic testing.
The reported observations are classified as evidence level D in the supplied object. Whether the short-term changes correspond to altered chronic disease progression remains unresolved; they do not establish a durable change in disease course. The paper presents no feline or FeLV-specific observations and provides no direct evidence about FeLV biology, feline neurologic disease, or feline clinical outcomes. Any proposed application to cats would require inference across both species and viruses.
What we know
A descriptive review of human HTLV-1-associated myelitis includes 45 cases across 27 publications, including the index case, with outcome-related data for 33 cases in Table 2. The RESULTS section reports radiographic myelitis in 98%, longitudinally extensive myelitis in 91%, and focal myelitis in 7%; the abstract differs, reporting 93% for longitudinally extensive myelitis. These are proportions in selected published cases, not population estimates or validated measures of diagnostic performance. Reporting of AQP4 and MOG IgG testing is incomplete. The reported observations are classified as evidence level D.
What we don't know
Whether short-term changes correspond to altered chronic disease progression remains unresolved. Limited follow-up and gaps in testing constrain interpretation; unreported testing does not mean a negative result or establish diagnostic misclassification. This paper provides no direct evidence about FeLV, feline neurologic disease, or clinical outcomes in cats.
Evidence
EvidenceLevel D — Indirect evidence: other species or retrovirusConfidence 100/100
Reported testing for AQP4 and MOG IgG was absent in cases published before 2009 and incomplete among subsequently published cases.
Excerpt verified in the source — verbatim, in the source's own language“No cases published before 2009 (21 total) reported testing for AQP4 or MOG IgG, and of the remaining 24 cases, 12 (50%) reported testing for AQP4 IgG and 7 (29%) tested MOG IgG.”
The source documents incomplete reporting of tests relevant to competing diagnoses. Unreported testing is not a negative result, and this limitation does not itself prove that any case was misclassified.
EvidenceLevel D — Indirect evidence: other species or retrovirusConfidence 100/100
In the reviewed human cases, the RESULTS section reports radiographic myelitis in 98%, longitudinally extensive myelitis in 91%, and focal myelitis in 7%.
Excerpt verified in the source — verbatim, in the source's own language“Most patients had radiographic features of myelitis (98%), with 91% showing a longitudinally extensive myelitis and 7% showing focal myelitis.”
These are descriptive proportions in selected published cases, not population prevalence estimates or validated diagnostic performance measures. The RESULTS section and Table 2 support 91% for longitudinally extensive lesions, whereas the abstract reports 93%. No uncertainty estimates accompany these proportions.
EvidenceLevel D — Indirect evidence: other species or retrovirusConfidence 100/100
The review pooled the index patient's data with systematically collected published cases of rapidly progressive or relapsing HTLV-1-associated myelitis that included spinal imaging.
Excerpt verified in the source — verbatim, in the source's own language“To supplement the literature review, her data were pooled along with systematically collected clinical, diagnostic, and treatment data from published cases of rapidly progressive or relapsing myelitis associated with HTLV-1 that included spine imaging during diagnostic evaluation.”
This describes a human case-based review, not a controlled experiment. Requiring spinal imaging constrains case selection. It supplies no direct feline or FeLV evidence.
Open questionConfidence 99/100
Whether the reported short-term changes correspond to altered chronic disease progression remains unresolved.
The abstract explicitly identifies chronic disease progression as requiring further clarification, and the body reports limited longitudinal follow-up. Short-term observations do not establish a durable change in disease course or any implication for FeLV.
Provenance
Source: Rapidly Progressive and Relapsing Myelitis With Human T Lymphotropic Virus Type 1: A Case Report and Review of the Literature.
AVA